Revolutionizing ALS Models, Novel Biomarkers & Clinical Endpoints to Accelerate Future ALS Approvals Following the approval of Amylyx’s Relyvrio and the upcoming Biogen/Ionis Tofersen FDA decision on the basis of…
A time to connect and collaborate to advance community health, well-being, and equity. Long-standing health care disparities and inequities still persist. Systemic drivers such as structural racism and economic disadvantages…
Amyotrophic lateral sclerosis (ALS) is a rapidly progressive, invariably fatal neurological disease that attacks motor neurons and leads to their gradual degeneration and death, often within two years of onset.…